D. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $10.00

Immunic (NASDAQ:IMUX - Free Report) had its price target cut by D. Boral Capital from $17.00 to $10.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also commented on IMUX. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. Wall Street Zen lowered shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. B. Riley reiterated a "buy" rating and issued a $5.00 price objective (down from $6.00) on shares of Immunic in a research report on Friday, May 23rd. Finally, William Blair restated an "outperform" rating on shares of Immunic in a report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Immunic has an average rating of "Buy" and a consensus target price of $11.60.

Immunic Stock Up 2.6%

Shares of Immunic stock traded up $0.02 on Thursday, hitting $0.68. The company's stock had a trading volume of 858,742 shares, compared to its average volume of 783,047. Immunic has a 52-week low of $0.56 and a 52-week high of $2.11. The firm has a fifty day moving average price of $1.00 and a 200-day moving average price of $1.06. The company has a market capitalization of $64.87 million, a P/E ratio of -0.55 and a beta of 1.73.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). As a group, analysts expect that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after acquiring an additional 415,104 shares during the period. Aberdeen Group plc acquired a new stake in Immunic during the 1st quarter worth approximately $1,155,000. 683 Capital Management LLC increased its position in Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares in the last quarter. Millennium Management LLC increased its position in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.